Diabetic Neuropathy Clinical Trial
Official title:
Centella Asiatica Triterpene Extract for Diabetic Neuropathy -- a Pilot Study
The purpose of this protocol is to investigate the safety, tolerability and effectiveness of CAST as a treatment for diabetic neuropathy. The primary outcome measure will be Total Neuropathic Symptom Score. Secondary outcomes will be neurological disability score, nerve conduction measurements and quantitative sensory testing. Statistical analyses will compare changes from baseline for CAST- and placebo-treated groups at both time points, compare effects of CAST at 6 and 12 months and, if numbers permit, compare doses.
This study is a clinical trial investigating the effect of an herbal supplement called CAST
on diabetic neuropathy. CAST is an herb commonly used in traditional Indian medicine. In
this tradition, it is used to increase memory, treat wounds and sores, skin diseases, and
neurological conditions such as epilepsy. The herb has had growing popularity in the US;
parts are sold as the dietary supplement "gotu kola" and used to improve blood circulation
and help heal wounds. Unlike many other herbs, CAST has been extensively researched for many
of the above conditions. The compounds found in CAST make it a very promising potential
treatment for diabetic neuropathy because of its effect on blood circulation and growth of
nerves.
Subjects will receive informed consent. They will then be screened for eligibility before
entering the study. A medical history will be taken and subjects will have a neurological
exam and vital signs taken. Subjects will have their blood drawn and will also give a urine
sample for routine testing. Subjects will have an electrocardiogram (ECG) to check their
heart. If a subject is a woman who is at risk of getting pregnant, she will have a urine
pregnancy test.
If the subject is eligible for participation in the study, they will return for a total of
nine additional study visits over the course of a year. Subjects will be randomly assigned
to either receive the active supplement (CAST) or a placebo. A placebo is a pill that
tastes, looks, and smells like the study drug but has no real medicine (or supplement) in
it. Subjects have a 50% chance of receiving the active supplement. Neither the subject nor
the study staff will know who receives the active supplement or the placebo. At visits 2, 7
and 10, subjects will get a comprehensive assessment of their neuropathy symptoms. This will
include a Neurological Disability Score assessment, a nerve conduction study and a
Quantitative Sensory Test.
Subjects enrolled in the study will begin taking their study pills at the beginning of week
1 of the study. During the first 12 weeks, subjects will be asked to increase their dose by
one pill every four weeks. Therefore, they will increase the number of CAST or placebo pills
from 60mg twice daily to 60mg four times daily, or the highest dose that does not cause side
effects. Dr. Lou will monitor subjects for side effects of the study supplement. At each
study visit, blood and urine samples will be taken for safety analysis, including liver and
kidney function, and glucose control, and an ECG will be done to monitor heart activity.
Subjects will be contacted by the study coordinator via phone call once per week during the
first three months of the study. During the remainder of the study, they will be called once
each month that they are not scheduled for an appointment. Treatment will conclude after one
year.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04025320 -
The Effect of Intraneural Facilitation Therapy on Diabetic Patients With Peripheral Neuropathy
|
N/A | |
Completed |
NCT02659007 -
Less Neuropathy After Yoga- Managing Diabetic Neuropathy With Yoga
|
Phase 1 | |
Completed |
NCT01953757 -
A Nutritional Intervention for Diabetic Neuropathy (WCCR-DN2)
|
N/A | |
Completed |
NCT01707979 -
NIR- and Multifrequent Impedance Spectroscopy on the Skin in Type 1 Diabetes
|
N/A | |
Completed |
NCT00576277 -
Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain
|
Phase 1/Phase 2 | |
Completed |
NCT00830011 -
Cognitive Behavioral Therapy for Painful Diabetic Neuropathy
|
N/A | |
Completed |
NCT00235443 -
A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy
|
Phase 2/Phase 3 | |
Completed |
NCT00931879 -
Lovaza® and Microvascular Function in Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT00190970 -
The Effect of Ruboxistaurin on Small Fiber Function
|
Phase 2 | |
Completed |
NCT00101426 -
Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy
|
Phase 3 | |
Completed |
NCT00238550 -
Study of CBME in the Relief of Painful Diabetic Neuropathy
|
Phase 2 | |
Completed |
NCT05573685 -
Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMoâ„¢ Component Training
|
N/A | |
Recruiting |
NCT02341261 -
Activity for Diabetic Polyneuropathy
|
N/A | |
Completed |
NCT01822925 -
Study of DA-9801 to Treat Diabetic Neuropathy
|
Phase 2 | |
Completed |
NCT01690962 -
A Nutritional Intervention for Diabetic Neuropathy
|
N/A | |
Terminated |
NCT00993018 -
A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy
|
Phase 2 | |
Withdrawn |
NCT02315235 -
The Peripheral Mobilized Mononuclear Cell-based Therapy in Patient With Diabetic Neuropathy
|
N/A | |
Completed |
NCT00496457 -
Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy
|
Phase 2 | |
Recruiting |
NCT02606747 -
The Balance Control Mechanism of DPN Patients
|
N/A | |
Completed |
NCT02068027 -
Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy
|
Phase 2 |